Recursion Pharmaceuticals Bolsa (NASDAQ: RXRX)

Últimas noticias sobre Recursion Pharmaceuticals (NASDAQ:RXRX) Bolsa

Recursion Pharmaceuticals

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals Inc

Goldman Sachs analyst Ryan Nash maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Buy and raises the price target from $50 to $60.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on Truist Finl, Raises Price Target to $60

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more
GLP-1 drugs expected to generate multi-hundreds of billions of revenues in the years to come
KELOWNA, BC / ACCESSWIRE / November 26, 2024 / Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXXW#NASDAQ">LEXXW</a>) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following strategic update.
Today's GLP-1 drug market consists primarily of semaglutide (Wegovy&#xAE;, Ozempic&#xAE;, and Rybelsus&#xAE;), owned by Novo Nordisk&#xAE;; and tirzepatide (Zepbound&#xAE;, Mounjaro&#xAE;), owned by Eli Lilly&#x2122;. All five of those drug brands, with the exception of Rybelsus&#xAE;, are administered by injection, whereas Rybelsus&#xAE; is the only oral tablet currently approved by the FDA today. While these two drugs were originally approved by the FDA for diabetes management, weight-loss approvals soon followed and <a href="https://pr.report/4ja2">Wegovy&#xAE; was also approved by the FDA</a> in March 2024 to reduce the risk of cardiovascular death, heart attack and stroke.
Acceptance and use of these two drugs by the public has resulted in unprecedented demand, with estimates of 2024 revenue between them of <a href="https://pr.report/4ja3">~$30 billion, compared to just $300 million in 2018</a>, an increase of 100x or 10,000%.

Biotech

General

LEXX

LEXXW

Lexaria Bioscience Provides Strategic Update; Says Semaglutide Being Investigated For Applications In Heart Disease, Alzheimer's, Liver Disease, And More; GLP-1 Drugs Expected To Generate Multi-Hundreds Of Billions Of Revenues In The Years To Come

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares are trading lower in the <a target="_blank" href="https://www.benzinga.com/24/11/42165679/nio-analyst-sees-tougher-path-to-profitability-downgrades-ev-maker-to-sell-what-you-need-to-know" rel="noreferrer noopener">premarket session on Tuesday.</a>
The Chinese EV manufacturer recently marked its 10th anniversary, with the company&#8217;s founder, chairman, and CEO, William Li, addressing employees through an internal letter.
In the message, Li emphasized the critical importance of the next two years for the company&#8217;s future, <a target="_blank" href="https://cnevpost.com/2024/11/25/nio-10th-anniversary-william-li-internal-letter/" rel="noreferrer noopener">reported</a> CnEV Post. Li outlined key objectives, including the launch of competitive new products and enhancing operational efficiency.
These efforts are aimed at doubling NIO&#8217;s sales in the coming year and achieving profitability by 2026, which he described as non-negotiable goals. Li urged the team to focus their full energy on meeting these targets.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more" rel="noreferrer noopener">J.M. Smucker Q2: Earnings Beat, 17% Sales Surge, FY25 EPS Outlook Boost &amp; More</a>
This week, Goldman Sachs analyst Tina Hou downgraded NIO from&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">Neutral to Sell</a> and lowered the price target from&nbsp;$4.80&nbsp;to&nbsp;$3.90, citing competitive pressures <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings" rel="noreferrer noopener">and a difficult path to profitability ahead</a>.
The analyst notes NIO is unfavorably positioned heading into 2025 given the slow production ramp of&nbsp;Onvo and the company&#8217;s <a target="_blank" href="https://www.benzinga.com/tech/24/11/41703522/ev-maker-nio-marks-battery-swap-network-milestone-rumors-swirl-around-2nd-onvo-electric-suv" rel="noreferrer noopener">limited new model pipeline.</a>
Recently, NIO guided deliveries of 72,000–75,000 units for the fourth quarter, or a 43.9% – <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42084907/nio-q3-earnings-11-6-gain-in-vehicle-deliveries-margins-improve-issues-robust-q4-delivery-outlook" rel="noreferrer noopener">49.9% year-over-year increase.&nbsp;</a>
The company expects&nbsp;fourth-quarter revenue&nbsp;of $2.804 billion &#8211; $2.904 billion, representing 15.0% – 19.2% year-over-year growth.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, NIO stock has lost over 35% in the past year. Investors can gain exposure to the stock via&nbsp;Invesco Golden Dragon China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGJ#NASDAQ">PGJ</a>).
Price Action: NIO shares are trading lower by 1.29% to $4.61 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades" target="_blank" rel="noreferrer noopener">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo by Sundry Photography on Shutterstock.

Equities

Markets

Movers

Media

PowerShares Golden Dragon Halter USX China Portfolio

What's Going On With NIO Stock Today?

Goldman Sachs analyst Ryan Nash maintains Synovus Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNV#NYSE">SNV</a>) with a Neutral and raises the price target from $52 to $62.

Goldman Sachs Maintains Neutral on Synovus Finl, Raises Price Target to $62

Goldman Sachs analyst Ryan Nash maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Buy and raises the price target from $29 to $33.

Goldman Sachs Maintains Buy on Regions Finl, Raises Price Target to $33

Goldman Sachs analyst Gabriela Borges maintains Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) with a Neutral and raises the price target from $19 to $21.

PYCR

Goldman Sachs Maintains Neutral on Paycor HCM, Raises Price Target to $21

Goldman Sachs analyst Ryan Nash maintains M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) with a Neutral and raises the price target from $216 to $243.

Goldman Sachs Maintains Neutral on M&T Bank, Raises Price Target to $243

Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) reported better-than-expected third-quarter results and raised its 2024 <a href="https://www.benzinga.com/quote/bbwi/earnings">outlook on Monday.</a>
BBWI&#8217;s third-quarter adjusted earnings per share of 49 cents, beating the analyst consensus of 47 cents. Quarterly sales of $1.610 billion, a growth of 3.1% year-over-year, above the street view of $1.579 billion.
Gina Boswell, CEO of Bath &amp; Body Works, commented, &#8220;Our strong results exceeded the high end of our net sales and earnings per diluted share guidance. As a result, we are raising our full-year guidance to fully reflect this outperformance.&#8221;
The company raised fiscal 2024 guidance and now expects net sales to decline 2.5% – 1.7% (prior view: decline of 4% – 2%), including a 100-basis-point headwind from the 53rd week in 2023. Adjusted earnings per share are projected at $3.15 – $3.28 (prior view $3.06 – $3.26) versus the $3.18 consensus.
Bath &amp; Body Works shares gained 16.5% to close at $35.78 on Monday.
These analysts made changes to their price targets on Bath &amp; Body Works following earnings announcement.
<ul>
<li>Piper Sandler analyst Korinne Wolfmeyer maintained Bath &amp; Body Works with a Neutral and raised the price target from $35 to $36.</li>
<li>Barclays analyst Adrienne Yih maintained Bath &amp; Body Works with an Underweight and raised the price target from $28 to $34.</li>
</ul>
Considering buying BBWI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-1024x562.png" alt="" class="wp-image-665566" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091838/image-283.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

Earnings

Trading Ideas

BBWI

Bath & Body Works Analysts Boost Their Forecasts After Strong Earnings

Emerald is a leading commercial vehicle manufacturer and seller of refrigerated trucks and vans
The refrigerated Class 3 EV box truck opens new rapidly expanding categories for home delivery, frozen food, grocery and beverage transportation
 &nbsp;
BREA, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- <a href="https://www.globenewswire.com/Tracker?data=wFgf3qyya1KMke66r447VNDvrYRea54HMKKRkEIQo7Ly6CoQ822jOQuk85LNxNhZooU03MseZ8fDjALtlgbzIKIt_7OpXeZw6soRqa3qwxk=">Mullen Automotive, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) ("Mullen" or the "Company"), an electric vehicle ("EV") manufacturer, announces today that <a href="https://www.globenewswire.com/Tracker?data=_KqftE2Zw2BKCjE93TpWGt5-j6V6zVcnf-xlK3C_70G2VYB_cBF1YF-BHGPizrPq3GQMdfRLSGcKNe4KxVHmMzA-m4CuMgQqqHWVr8EjgONJBA1I_k_zte6g4XM-yxYU7UW6JQJchokpGnydx1lX_A==">Emerald Transportation Solutions</a> ("Emerald"), a premier commercial refrigeration ("reefer") vehicle upfitter, is working with the Papé Group ("Papé") to develop an advanced reefer upfit for the Mullen THREE, a Class 3 all-electric truck. The refrigerated Class 3 EV box truck opens new rapidly expanding categories for home delivery, frozen food, grocery and beverage transportation.

MULN

Mullen Announces  Emerald Transportation Solutions Is Working With The Papé Group To Develop An Advanced Reefer Upfit For The Mullen THREE, Class 3 All-Electric Truck

Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) will be reporting its third-quarter earnings on Tuesday. Wall Street expects $2.05 in EPS and $24.65 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=DELL" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 93.61% over the past year, 19.48% over the past month.
Let&#8217;s look at what the charts indicate for Dell stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/24/11/42189449/how-to-earn-500-a-month-from-dell-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Dell Stock Ahead Of Q3 Earnings</a>
<h2 class="wp-block-heading">Dell Technical Setup Ahead Of Q3 Earnings&nbsp;</h2>
Dell stock is showcasing a strong bullish trend, with its share price at $144.16 comfortably above the five-day, 20-day and 50-day exponential moving averages. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM.png" alt="" class="wp-image-665421" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26084135/Screenshot-2024-11-26-at-6.02.20-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112624&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
This upward momentum is reinforced by the eight-day simple moving average (SMA) of $137.40, the 20-day SMA at $134.40 and the 50-day SMA at $126.41, all pointing to continued bullish strength. 
Additionally, the stock remains well above its 200-day SMA of $122.23, underscoring long-term upward momentum.
However, while the Moving Average Convergence Divergence (MACD) at 4.36 confirms the bullish trend, and the RSI of 66.17 indicates strong buying momentum, the RSI&#8217;s proximity to overbought territory suggests a risk of bearish consolidation. 
Slight selling pressure also hints at potential near-term volatility. While the trend remains firmly bullish, investors should monitor for signs of cooling off as the stock approaches overbought levels.
<h2 class="wp-block-heading">Analysts See 7% Upside</h2>
Ratings &amp; Consensus Estimates: <a href="https://www.benzinga.com/quote/DELL/analyst-ratings" target="_blank" rel="noreferrer noopener">The consensus analyst rating</a> on Dell stock stands at a Buy currently with a price target of $121.73. Recent analyst ratings from Evercore ISI Group, Wells Fargo and Morgan Stanley suggest an average price target of $154.67 for Dell stock implying a 7% upside.
Price Action: Dell stock closed the trading day Monday at $144.16, down 0.03%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42185644/us-stocks-may-have-a-slow-start-as-trumps-tariff-threat-begins-to-thwart-relief-rally-analysts-remain-positive-on-market-breadth-ai-linked-sectors-and-stocks">US Stocks May Have A Slow Start As Trump&#8217;s Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

DELL

Dell's 93% Rally Hits Q3 Crossroads – What's Next For The Stock?

Canopy Growth Corporation (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WEED#TSX">WEED</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) announced on Tuesday that its board of directors has named Luc Mongeau as the company's next chief executive officer, effective Jan. 6, 2025.
Mongeau, a CPG veteran and board member at the Canadian cannabis giant, succeeds CEO David Klein, who announced his plans to retire in August.
Klein, who <a href="https://www.benzinga.com/markets/cannabis/24/08/40417074/head-of-canadian-cannabis-giant-canopy-growth-to-retire-at-the-end-of-this-fy">joined</a> Canopy Growth in January 2020, led the Ontario-based company through transformation and development to meet opportunities within the global cannabis market.
&#8220;Under his leadership, the company established a foundation for multi-market cannabis leadership through its transformation to an asset-light model in Canada and across a range of international markets, including Germany,&#8221; the company said in a press release. &#8220;In addition, Mr. Klein oversaw the launch and advancement of Canopy USA as a first-of-its-kind structure to offer the Company's shareholders unique exposure to the rapid growth and opportunity presented by the U.S. cannabis market ahead of federal permissibility.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40419783/canopy-growth-ceo-departure-leaves-nasdaq-listed-company-poised-for-profit-surge-what-investors-">Canopy Growth CEO Departure Leaves Nasdaq-Listed Company Poised For Profit Surge &#8211; What Investors Need To Know</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">New CEO</h3>
Mongeau, who has over 25 years&#8217; experience as a senior executive, has most recently served as the CEO of North America&#8217;s e-commerce provider for residential and commercial furniture ESolutions Furniture, formerly Bestar-Bush. He previously held the role of president for Weston Foods as well as president of Mars Petcare North America.
Mongeau joined Canopy as an observer in early 2023 and as a board member in Feb. 2024.
The new appointment comes simultaneously with the company's influence extending in the U.S. via Canopy USA, LLC.
The new U.S.-domiciled holding company <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/10/29418334/this-is-how-its-done-why-is-canopys-us-consolidation-plan-blueprint-for-other-canad">first introduced</a> in 2022, represents Canopy Growth's strategy for capturing the U.S. cannabis market. The business strategy, which included acquisitions of Wana Brands and Jetty, as well as holding a minority stake in TerrAscend Corp. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TSND#TSX">TSND</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/TSNDF#OTCQX">TSNDF</a>), also includes the acquisition of Acreage Holdings, Inc. (CSE:<a class="ticker" href="https://www.benzinga.com/stock/ACRG#CSE">ACRG</a>, ACRG.B.U)) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/ACRHF#OTCQX">ACRHF</a>, ACRDF)) which is expected to close in early 2025, according to Canopy.
<h3 class="wp-block-heading">What's Next</h3>
Mongeau will continue serving as a member of the board in his new role as CEO.
To support an efficient transition, Klein will continue in his role as CEO and a director on the board until the effective date of Mongeau&#8217;s appointment as CEO.
On Jan. 6, 2025, Klein will step down as a member of the board and will shift into a special advisor role until Aug. 31, 2025.
&#8220;I am honored to lead Canopy Growth into this exciting next chapter, and I am confident that our vision, dedication to our consumers, and the commitment of our team members will continue to position us for long-term success and value creation,&#8221; Mongeau said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a></li>
</ul>
<h3 class="wp-block-heading">CGC Price Action</h3>
Canopy Growth's shares traded 0.2120% lower at $4.1412 per share during the pre-market session on Tuesday morning.

Cannabis

ACRHF

CSE:ACRG

TSNDF

TSX:TSND

TSX:WEED

WEED

Canopy Growth Names New CEO Who Will Succeed David Klein Amid US Expansion

Analog Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) stock traded higher Tuesday after the company reported&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42185542/analog-devices-reports-fourth-quarter-and-fiscal-2024-financial-results" rel="noreferrer noopener">fiscal fourth-quarter&nbsp;results</a>.
The company&#8217;s revenue declined 10% year-on-year to $2.44 billion, beating the analyst consensus estimate of $2.40 billion. Adjusted EPS of $1.67 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.64</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42186138/taiwan-semis-growth-fuels-us-rise-to-second-in-chipmaking" rel="noreferrer noopener">Taiwan Semi&#8217;s Growth Fuels US Rise To Second In Chipmaking: Report</a>
Analog Devices&#8217;&nbsp;Industrial revenue declined&nbsp;by 21% Y/Y&nbsp;to $1.07 billion. Automotive&nbsp;revenue decreased 2%&nbsp;Y/Y&nbsp;to $716.96 million.
Communications revenue declined by 18% to $275.57 million, and Consumer revenue increased by 31% to $379.69 million.
The adjusted gross margin declined by 230 bps to 67.9% as lower revenue weighed on the profits. The adjusted operating margin fell by 360 bps to 41.1%.
Analog Devices held $2.36 billion in cash and equivalents&nbsp;as of November 2, 2024, generating $1.05 billion in operating cash flow.
According to CEO and Chair Vincent Roche, Analog Devices reported revenue, profitability, and earnings per share exceeding its midpoint guidance, reflecting strong business momentum and effective execution. Despite unprecedented inventory challenges leading to a historic revenue decline in fiscal 2024, the company maintained operating margins above 40%, showcasing the resilience of its business model.
Analog Devices&#8217; quarterly cash dividend of $0.92 per outstanding share of common stock will be paid on December 20 to all shareholders of record at the close of business on December 9.
CFO Richard Puccio noted a rebound in bookings during the fourth quarter, especially in the Automotive segment, following a temporary decline in the third quarter. While macroeconomic uncertainties continue to temper recovery, Analog Devices remains cautiously optimistic about achieving significant growth in fiscal 2025.
Outlook: Analog Devices expects fiscal first-quarter 2025 revenue of $2.35 billion, +/- $100&nbsp;million, versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $2.34 billion</a>. The company projects adjusted EPS of $1.53,&nbsp;+/-$0.10, against the consensus of $1.56.
Price Action: ADI stock traded higher by 5.47% at $235.80 premarket at&nbsp;the last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42137930/boeing-secures-238-billion-deal-for-advanced-kc-46a-tankers" target="_blank" rel="noreferrer noopener">Boeing Secures $2.38 Billion US Air Force Deal for Advanced KC-46A Tankers</a></li>
</ul>

Guidance

Dividends

Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook & More

Xiaomi Corp. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) is set to launch its own mobile processor for future smartphones, aiming to lessen its dependency on foreign suppliers like Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) and MediaTek Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDTKF#OTC">MDTKF</a>). 
What Happened: This strategic move aligns with Beijing&#8217;s push for local firms to minimize reliance on foreign technology. Xiaomi&#8217;s initiative comes amid a broader trend of tech giants investing in semiconductor development, a critical area in the ongoing tech race with the United States, according to&nbsp;<a href="https://www.bloomberg.com/news/articles/2024-11-26/xiaomi-readies-own-mobile-chip-pressuring-mediatek-and-qualcomm">Bloomberg</a> on Tuesday, the chip&#8217;s mass production is slated for 2025.
Xiaomi&#8217;s chipmaking efforts could potentially challenge its current manufacturing partner, Taiwan Semiconductor Manufacturing Co., (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) especially as the latter faces increasing pressure from U.S. authorities regarding its dealings with Chinese clients.
See Also:&nbsp;<a href="https://www.benzinga.com/24/11/42154224/weekend-round-up-ai-dominates-headlines-with-nvidia-elon-musk-and-hollywoods-big-names?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Weekend Round-Up: AI Dominates Headlines With Nvidia, Elon Musk, And Hollywood&#8217;s Big Names</a>
In addition to mobile processors, Xiaomi&#8217;s investment in research and development is projected to rise to 30 billion yuan in 2025, focusing on artificial intelligence and operating system enhancements. Chairman and CEO&nbsp;Lei Jun&nbsp;announced these plans during a recent company event, emphasizing the importance of core technologies, Bloomberg reported.
Why It Matters: Previously, Xiaomi launched its first in-house chip &#8220;Surge S1,&#8221; a mid-range system-on-chip (SoC) in 2017 for its Mi 5C smartphone. However, the adoption was limited due to competition from Qualcomm and MediaTek.
A reported attempt to develop the &#8220;Surge S2&#8221; chip was halted due to production delays and technical hurdles in 2020, as <a href="https://www.gizmochina.com/2020/03/18/xiaomis-surge-chip-development-reportedly-abandoned-shifting-focus-to-low-power-bl-rf-chips/">per</a> Gizmochina.
The development of Xiaomi&#8217;s in-house chips is a significant step in China&#8217;s broader strategy to become self-reliant in critical technology sectors. This move is part of a larger trend where <a href="https://www.benzinga.com/24/11/42153854/apples-future-ventures-huaweis-new-chip-and-googles-antitrust-woes-this-week-in-appleverse">Chinese tech companies are increasingly investing in semiconductor technology</a> to reduce dependence on foreign suppliers. Recently, in a move to challenge the dominance of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Huawei introduced its latest flagship smartphone, the Mate 70, featuring the HarmonyOS Next. This new operating system has been developed entirely in-house, marking a significant step for Huawei in the mobile OS market.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/11/42157390/intels-federal-chips-grant-shrinks-below-8b-as-biden-administration-recalibrates-chips-act-funding-report?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Intel&#8217;s Federal Chips Grant Shrinks Below $8B As Biden Administration Recalibrates CHIPS Act Funding: Report</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo by Srikant_Photography on Shutterstock

AAPL

GOOG

GOOGL

MDTKF

QCOM

XIACF

Xiaomi Set To Challenge Qualcomm, MediaTek As It Ventures Into Chipmaking Once Again

Millennials are having fewer children than their parents did. While that might <a href="https://www.benzinga.com/personal-finance/24/07/39674955/millennials-slated-to-be-the-richest-generation-in-history-but-they-are-very-ill-prepared-how-wi">work for their personal budgets,</a> experts warn it could drag the economy down for decades.
James Pomeroy, a global economist at HSBC, paints a grim picture. &#8220;What you&#8217;re talking about is these birth rates dropping to very, very low levels, which over the course of time has huge impacts on the economy,&#8221; he told Business Insider. The U.S. birthrate has fallen dramatically – <a href="https://www.cdc.gov/nchs/data/vsrr/vsrr028.pdf">just 11.1 births per 1,000 people</a> in 2022, a 53% drop from 1960. And it's still dropping, around 2% each year.
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
</ul>
Why do fewer kids mean trouble? Lower birthrates mean fewer workers in the economy. That has a ripple effect. Todd Buchholz, a former White House economist, explains the challenges. &#8220;You find it more difficult to find somebody to cut your hair, do your nails, work on, set up the X-ray machines at the hospital,&#8221; he said. &#8220;The sheer decrease in the number of people … becomes a problem.&#8221;
Social Security is another big issue. By 2029, all baby boomers will be 65 or older, putting massive pressure on Medicare and Social Security. Buchholz says the system isn't ready. &#8220;We will have a great deal of trouble … figuring out how to pay the retirements. The promised retirement payments for senior citizens … are going to go in vast deficits.&#8221;
See Also: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a>
According to Buchholz, in the 1930s, there were 20 workers for every retiree. If trends continue, Buchholz says the ratio could drop to two workers per retiree. &#8220;That is simply not sustainable,&#8221; he warns.
The cost of living is a major factor for millennials. From housing to education, everything is more expensive. Some millennials are opting out of parenthood entirely. Many are part of the DINK (dual income, no kids) lifestyle, <a href="https://www.benzinga.com/real-estate/24/11/41700720/better-off-redfin-survey-reveals-69-of-millennial-and-gen-z-homeowners-see-wealth-surge-compared-to">choosing to spend their money</a> on vacations, hobbies and luxuries instead of raising children.
Pomeroy says cultural attitudes also play a role. &#8220;I think it&#8217;s a net negative to have fewer children when the choice is between having a child and investing in a new Sony PlayStation,&#8221; he said.
Buchholz agrees, adding that society needs a mindset shift. He suggests reframing the narrative around children. &#8220;People who have children feel that they live more than once,&#8221; he said, highlighting the fulfillment that family can bring.
So what's next? Fixing this problem won't be easy. Government policies like housing reforms or financial incentives could help. But experts say it'll take a long time to see results. America faces a future with fewer kids, fewer workers and tough economic challenges ahead.
Read Next:
<ul>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

The U.S. Birthrate Has Plunged 53% Since 1960. An HSBC Economist Is Sounding The Alarm

HC Wainwright &amp; Co. analyst Arthur He downgrades Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) from Buy to Neutral and lowers the price target from $20 to $9.

Downgrades

PSTX

HC Wainwright & Co. Downgrades Poseida Therapeutics to Neutral, Lowers Price Target to $9

<ul>
<li>NVDA</li>
<li>ACHR</li>
<li>MSTR</li>
<li>RIVN</li>
<li>RKLB</li>
<li>TSLA</li>
<li>SMCI</li>
<li>$BTC</li>
<li>CORN</li>
<li>LOT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

ACHR

CORN

MSTR

NVDA

RIVN

RKLB

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 26, 2024 (Via Swaggy Stocks)

Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) reported better-than-expected third-quarter financial results and issued fourth-quarter guidance with its <a href="https://www.benzinga.com/quote/SMTC/earnings">midpoint above estimates</a>.
Semtech reported quarterly earnings of 26 cents per share which beat the analyst consensus estimate of 23 cents per share. The company reported quarterly sales of $236.80 million which beat the analyst consensus estimate of $232.06 million.
&#8220;We are very pleased to report broad-based growth across each of our end markets, and particularly in data center, where we project AI-driven product demand to be a long-term and transformational growth engine for Semtech. Our results validate that our customers and target markets are moving toward us and highlight the effectiveness of our initiatives to drive market share gain and SAM expansion,&#8221; said Hong Hou, Semtech&#8217;s president and chief executive officer. &#8220;I believe we have achieved multi-generational roadmap alignment with customers and aspire to become the partner of choice for key technical and product solutions we provide.&#8221;
Semtech shares gained 5% to close at $53.44 on Monday.
These analysts made changes to their price targets on Semtech following earnings announcement.
<ul>
<li>Needham analyst Quinn Bolton reiterated Semtech with a Buy and raised the price target from $50 to $70.</li>
<li>Northland Capital Markets analyst Gus Richard maintained the stock with an Outperform and raised the price target from $46 to $60.</li>
<li>Piper Sandler analyst Harsh Kumar reiterated Semtech with an Overweight and raised the price target from $60 to $75.</li>
<li>Stifel analyst Tore Svanberg maintained the stock with a Buy and boosted the price target from $58 to $65.</li>
</ul>
Considering buying SMTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="508" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282-1024x508.png" alt="" class="wp-image-665536" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282-1024x508.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282-768x381.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/26091231/image-282.png 1092w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>

SMTC

Semtech Analysts Raise Their Forecasts After Upbeat Earnings

Goldman Sachs analyst John Mackay maintains Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) with a Buy and raises the price target from $32 to $44.

Goldman Sachs Maintains Buy on Kodiak Gas Services, Raises Price Target to $44

Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares are trading higher Tuesday after the Biden-Harris Administration proposed a new rule to expand coverage of anti-obesity medications for Americans with <a href="https://www.benzinga.com/wiim/24/11/42186510/novo-nordisk-and-eli-lilly-shares-are-trading-higher-after-the-biden-harris-administration-proposed">Medicare and Medicaid</a>.
What Happened: The government has proposed a new rule to expand access to medications for obesity. In a statement released Monday, the Biden-Harris Administration said Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95% for some enrollees. Approximately 4 million Medicaid enrollees would also gain access to these medications.
&#8220;The President is proud of the fact that the Inflation Reduction Act allows Medicare to negotiate down the price of drugs, a tool that will help Medicare lower the cost of some of the most expensive medications in the program.&nbsp; That power to negotiate drug prices is critical because Americans pay two to three times more than people in other countries for their prescription drugs,&#8221; the White House said in a statement.
The move is part of the Biden-Harris Administration's&nbsp;national strategy on Hunger, Nutrition and Health&nbsp;focused on ending hunger and reducing diet-related diseases such as obesity.&nbsp;
The anti-obesity drug market has expanded in recent years with FDA approval for a new class of drugs like&nbsp;<a href="https://www.benzinga.com/markets/equities/24/11/42039286/eli-lillys-zepbound-mounjaro-shows-cardiovascular-benefits-in-patients-with-obesity-related-heart-failure">Eli Lilly's Zepbound</a>, which can cost close to $1,000 per month for those paying out-of-pocket. 
One of the main parts of the Biden-Harris Administration&#8217;s strategy involves recognizing the opportunity within Medicare and Medicaid to support access to nutritious foods, obesity counseling and other nutrition-related services.&nbsp;
&#8220;Obesity is a multi-faceted disease and we need to work on all levels from prevention to treatment to address this persistent challenge,&#8221; the White House said.
Eli Lilly&#8217;s Zepbound generated $1.26 billion in sales for the company in its most recent quarter. Eli Lilly said Mounjaro and Zepbound sales in&nbsp;the third quarter&nbsp;were negatively impacted by inventory decreases in the wholesaler channel.&nbsp;
See Also: <a href="https://www.benzinga.com/news/earnings/24/11/42188320/best-buy-says-q3-sales-little-softer-than-expected-on-lower-demand-for-appliances-and-gaming-trims-annual-forecast">Best Buy Says Q3 Sales &#8216;Little Softer Than Expected&#8217; On Lower Demand For Appliances And Gaming, Trims Annual Forecast</a>
LLY Price Action: Eli Lilly shares were up 3.58% at $782.00 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Eli Lilly Stock Is Rising Tuesday: What's Going On?

Goldman Sachs analyst John Mackay maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Buy and raises the price target from $26 to $29.

Goldman Sachs Maintains Buy on Kinder Morgan, Raises Price Target to $29

Recursion (RXRX) and Exscientia plc (EXAI) have each received overwhelming approval from their shareholders for the proposed combination between Re...

Recursion, Exscientia shareholders approve proposed combination

Nvidia discloses new stake in Applied Digital; maintains Arm Holdings, SoundHound stakes

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 7,493 calls trading, 2x expected, and implied vol increasing almost 4 points ...

Recursion Pharmaceuticals call volume above normal and directionally bullish

The latest announcement is out from Recursion Pharmaceuticals ( ($RXRX) ). In a strategic move, the Company finalized its acquisition of Exscientia...

Recursion Pharmaceuticals' Strategic Acquisition and Leadership Changes

Unusual total active option classes on open include: TORM plc (TRMD), TJX (TJX), Williams Sonoma (WSM), Recursion Pharmaceuticals (RXRX), Cipher Mi...

Unusually active option classes on open November 20th

Analyst Gil Blum of Needham maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report), retaining the price target of $11.00. Gi...

Strategic Mergers and Financial Strength: Recursion Pharmaceuticals' Path to Growth

Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline

20:03 EST Cathie Wood's ARK Investment buys 383K shares of Recursion Pharmaceuticals (RXRX) today Published first on TheFly – the ultimate source f...

Cathie Wood's ARK Investment buys 383K shares of Recursion Pharmaceuticals today

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report), reducing the p...

Hold Rating Recommended for Recursion Pharmaceuticals Post-Merger with Exscientia: Upside Potential Amidst Clinical Uncertainties

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vor Biopharma (VOR – Research Report), Recursion P...

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)

ANTX

APLD

CIFR

EXAI

NNOX

RXRX

SERV

SOUN

STLA

TRMD

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, PANL, BALY, RXRX on Behalf of Shareholders

Health Care

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K, RVNC, ARC, RXRX on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPTN, RVNC, K, RXRX on Behalf of Shareholders

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

Comments

Recursion Pharmaceuticals

Noticias

Últimas noticias sobre Recursion Pharmaceuticals (NASDAQ:RXRX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL